The present invention relates generally to obesity treatment and, more particularly, to the treatment of obesity by implanting a force producing device into a gastric lumen to create pressure on the inside surface of the lumen to reduce the effective volume of the lumen inducing a prolonged sense of satiety and/or and earlier feeling of satiation in the patient, and adjusting the device remotely or automatically.
Obesity is a medical condition affecting more than 30% of the population in the United States. Obesity affects an individual's personal quality of life and contributes significantly to morbidity and mortality. Obesity is most commonly defined by body mass index (BMI), a measure which takes into account a person's weight and height to gauge total body fat. It is a simple, rapid, and inexpensive measure that correlates both with morbidity and mortality. Overweight is defined as a BMI of 25 to 29.9 kg/m2 and obesity as a BMI of ≧30 kg/m2. Morbid obesity is defined as BMI≧40 kg/m2 or being 100 lbs. overweight. Obesity and its co-morbidities are estimated to cost an excess of $100 billion dollars annually in direct and indirect health care costs. Among the co-morbid conditions which have been associated with obesity are type 2 diabetes mellitus, cardiovascular disease, hypertension, dyslipidemias, gastroesophageal reflux disease, obstructive sleep apnea, urinary incontinence, infertility, osteoarthritis of the weight-bearing joints, and some cancers. These complications can affect all systems of the body, and dispel the misconception that obesity is merely a cosmetic problem. Studies have shown that conservative treatment with diet and exercise alone may be ineffective for reducing excess body weight in many patients.
Bariatrics is the branch of medicine that deals with the control and treatment of obesity. A variety of surgical procedures have been developed within the bariatrics field to treat obesity. The most common currently performed procedure is the Roux-en-Y gastric bypass (RYGB). This procedure is highly complex and is commonly utilized to treat people exhibiting morbid obesity. In a RYGB procedure, a small stomach pouch is separated from the remainder of the gastric cavity and attached to a resected portion of the small intestine.
This resected portion of the small intestine is connected between the “smaller” gastric pouch and a distal section of small intestine allowing the passage of food therebetween. The conventional RYGB procedure requires a great deal of operative time and is not without procedure related risks. Because of the degree of invasiveness, post-operative recovery can be quite lengthy and painful. Still more than 100,000 RYGB procedures are performed annually in the United States alone, costing significant health care dollars.
In view of the highly invasive nature of the RYGB procedure, other less invasive procedures have been developed. These procedures include gastric banding, which constricts the stomach to form an hourglass shape. This procedure restricts the amount of food that passes from one section of the stomach to the next, thereby inducing an early feeling of satiation and/or a prolonged feeling of satiety. A band is placed around the stomach near the junction of the stomach and esophagus. The small upper stomach pouch is filled quickly, and slowly empties through the narrow outlet to produce the feelings of satiety and satiation. In addition to surgical complications, patients undergoing a gastric banding procedure may suffer from esophageal injury, spleen injury, band slippage, band erosions, reservoir deflation/leak, and persistent vomiting. Other forms of bariatric surgery that have been developed to treat obesity include Fobi pouch, bilio-pancreatic diversion, vertical banded gastroplasty and sleeve gastrectomy. As aspects of some of these procedures, including RYGB, involve stapling a portion of the stomach, many bariatric procedures are commonly referred to as “stomach stapling” procedures.
For morbidly obese individuals, RYGB, gastric banding or another of the more complex procedures may be the recommended course of treatment due to the significant health problems and mortality risks facing the individual. However, there is a growing segment of the population in the United States and elsewhere who are overweight without being considered morbidly obese. These persons may be 20-30 pounds overweight and want to lose the weight, but have not been able to succeed through diet and exercise alone. For these individuals, the risks associated with the RYGB or other complex procedures often outweigh the potential health benefits and costs. Accordingly, treatment options should involve a less invasive, lower cost solution for weight loss. Further, it is known that modest reductions in weight may significantly decrease the impact of co-morbid conditions including, but not limited to type 2 diabetes mellitus. For this reason as well, a low cost, low risk procedure with effective weight loss results would provide significant benefit to both patients and health care providers.
Accordingly, it is desirable to have a low risk, minimally invasive procedure for treating obesity. It is desirable to have a procedure in which a treatment device can be easily and safely implanted into the gastric cavity of a patient to reduce the effective volume of the cavity. Additionally, it is desirable to have such a device that can assume an initial deploying configuration, and then be transformed into a second operable configuration within the gastric cavity. Further, it is desirable that the device apply outward pressure against the wall of the gastric cavity in the operable configuration in order to create a sensation of fullness within the patient. Further, it is desirable to have a method of treating obesity by reducing the effective volume within the gastric cavity. Additionally, it is desirable to have a method of treating obesity which includes applying pressure against the inside surface of the gastric cavity to create a feeling of fullness. It is desirable that the obesity treatment method be low cost and minimally invasive so as to be beneficial to a large number of obese patients. Further, it is desirable that the obesity treatment be easily and safely reversible. Additionally, it is desirable to adjust the device over time to accommodate individual patients and extend the durability of the treatment effect. The present invention provides an implantable obesity treatment device and method of treating obesity which achieves these objectives.
The present invention pertains to devices and methods for remotely adjusting a satiety-inducing gastric implant. The implant is shaped as an open loop within a gastric lumen to hold the walls of the lumen taut, thereby reducing the effective volume per tissue surface area within the lumen. The stretching of the stomach tissue inhibits gastric motility and delays gastric emptying. When utilized within the stomach, the implant can induce a prolonged hormonal response within the body to reduce the desire to eat. In addition, the implant can bias stretch receptors within the stomach to signal an early sense of satiety. The implant is shaped as a semi-rigid open loop (e.g., U-shaped, V-shaped, etc.) that applies an outward radial force in a single plane to flatten the stomach. Alternatively, the device may be shaped as a closed loop (e.g., O-Shaped, D-Shaped, ‘figure eight’ shaped, etc.). One example is a D shape in which the straight line of the D is hingedly attached to the loop of the curved part of the D. The device would be inserted either collapsed or straight, then formed into a closed loop. These loop features are important to the implant as they prevent the implant from exiting the gastric region. The implant has a minimum bend radius in the loop region to prevent it from passing through the pylorus and or esophagus (proximal or distal migration) where the coil device has a mechanical stop that prevents it from folding any smaller than the minimum bend radii. The force plane of the implant may change over time due to stomach motions. The implant is preferably installed and removed endoscopically and includes design features that prevent migration and erosion. Although less desirable, laparoscopic, open surgical techniques, or a combination thereof, may also be used to install and remove the implant. Examples of satiety-inducing gastric implants, optimal design features, as well as methods for installing and removing them are described in commonly owned and pending U.S. patent application Ser. No. 11/469,564, filed Sep. 1, 2006, and pending U.S. patent application Ser. No. 11/469,562, filed Sep. 1, 2006, which are hereby incorporated herein by reference in their entirety.
The present invention provides an implantable device for placement within a hollow body organ having an undeployed shape for delivery to the hollow body organ and a deployed shape within the hollow body organ. The device includes tensioning members for drawing and locking the ends of the device in a curved, deployed shape. Retained forces within the deployed device produce outward pressure on the hollow body organ to flatten the organ in the plane of the device, thereby reducing the effective volume within the organ.
The present invention also provides a method for treating obesity which includes passing an implantable device into a hollow body organ in an undeployed configuration and placing the device into a deployed configuration within the hollow body organ. The method includes means for remotely adjusting the device in order to optimize treatment effect. In the curved configuration, pressure is applied by the device against the interior of the hollow body organ, to flatten the organ in the plane of the device, thereby reducing the volume within the organ.
The device may have several effects on the stomach resultant from its action. The distension of the stomach at all times or periodically may trigger stretch receptors which in turn trigger a sense of satiation. At the same time, the device may limit the stomach's ability to expand, effectively reducing its capacity or fill volume. Additionally, the device may induce a hormonal effect due either to the triggering of the stretch receptors, contacting of various nerves on the stomach or other mechanism. Additionally, the device may prolong gastric emptying by preventing efficient antral contractions and/or partially blocking the pyloric outlet. Additionally, the device may provide a restrictive inlet into the stomach just distal to the esophagogastric junction. All of these may impact satiation (level of fullness during a meal, which regulates the amount of food consumed), or satiety (level of hunger after a meal is consumed, which regulates the frequency of eating.
The implant is preferably inserted trans-orally while deformed, folded, or otherwise placed into a relatively straight position, and is subsequently deployed into a different shape while inside the stomach lumen. The deployed configuration is flexible enough to allow some compression and movement relative to the stomach mucosa to prevent erosion, but rigid enough to prevent unwanted buckling and proximal or distal migration. The implant can be adjusted periodically to relieve the pressure on the gastric walls, or to alter the size or shape of the implant. The size, shape or stiffness of the implant may be adjusted multiple times after implantation as the patient acclimates to the device. The present invention provides for the remote accessing and adjustment of a satiety-maintaining and/or satiation inducing gastric implant. Remote access eliminates the need to intubate the patient endoscopically in order to adjust the implant.
Referring now to
The length of wire 52 within coil lumen 42 may be increased by turning knob 56 in an opposite direction to push on the wire. As wire 52 is pushed, an additional length of wire 52 is forced through sheath 54 and into lumen 42. When wire 52 is offset towards the inner diameter 110 of coil 20, pushing additional wire into lumen 42 allows the ends 24, 26 of the coil to move apart. As ends 24, 26 move apart, coil 20 expands, increasing the coil's force against the gastric walls. Likewise, when wire 52 is offset towards the outer diameter 111 of coil 20, pushing additional wire into lumen 42 will reduce the tension within coil 20, allowing ends 24, 26 of the coil to move closer together, thereby reducing the diameter of the coil. After wire 52 is adjusted, knob 56 is locked into position to secure the wire and prevent a subsequent change in wire tension.
In an alternative embodiment, sutures 60 may be comprised of a plurality of bioabsorbable materials that gradually degrade over time. The degradation period of the materials can vary between the various suture pieces, so that the sutures dissolve at different rates. The degradation rate can be controlled by changes in cross sectional area or in degradation rates of the material for example. The length of the degradation period corresponds to the length of the suture piece, so that the pieces dissolve in the order of increasing length to gradually expand the size of the coil. In this embodiment, coil expansion can be accomplished without penetrating the gastric cavity through port 44.
As shown in
In a slight modification to the embodiment shown in
A sensor 102 may be located within coil 90 to measure the fluid pressure within sacs 92 and channel 94. The signal from sensor 102 can be used to control fluid exchange with channel 94. In addition to fluid pressure, sensors may be located within or external to coil 90 to measure clinically relevant parameters such as conditions within the gastric cavity or from within the coil itself These measurements may be used to provide feedback either automatically or manually regarding operation of the coil. This feedback may be used to make adjustments to the coil. For example, a sensor could measure changes in the stomach pH, pressure, or internal device strains indicating that the patient was eating. The sensor could then generate a signal to increase the size of the coil in order to induce satiation sooner. When the readings returned to a previous level, indicating the patient was finished eating, the coil could be returned to a previous size. In one embodiment, this rate at which the coil returns to a previous size may be fast or slow, but is optimized to prolong feelings of satiety. A sensor within coil 90 could also be used to record operational data for the coil. This data could be retrieved from the coil during a medical checkup.
A sensor or array of sensors, not show, may be fixedly attached to the external surface of the coil to measure the interface pressure or force between the coil and stomach tissue. The feedback from these sensors can generate a signal indicating a threshold of stomach expansion. The sensor can be configured to measure positive and negative pressure changes which may indicate an increase or decrease in stomach size. A recording device may be used to record and transmit sensed data from the implant to the outside of the patient.
After insertion into the gastric cavity, the fill port 109 is accessed endoscopically in order to inject or withdraw fluid from balloon 108. In one embodiment, fill port 109 is releasably connected to a fluid delivery device outside of the patient prior to delivery of the device into the gastric cavity. Balloon 108 may be partially filled prior to introduction into the patient, but not to an extent that would hinder insertion. Once placed in the gastric cavity, balloon 108 may be filled to the desired pressure. After balloon 108 is filled, the fluid delivery device is disconnected from fill port 109.
Continued filling of balloon 108 creates opposing forces on widened areas 110 and 111 of lumen 108. The force provides for a rotational force of individual links 105 about pivot pin 106, expanding the coil as illustrated in Fig. The expanded coil places an outward force on gastric cavity 46, flattening the gastric lumen 113 as illustrated in
In another embodiment the in lumen of the coil is at least partially filled with an expandable material such as a hydrogel such that the band can be inserted endoscopically in a substantially flat configuration. Once deployed into the stomach could automatically expand to a predetermined size by at least partially exposing the internal hydrogel to stomach fluids. Alternatively, the coil can be of a hermetically sealed construction where the hydrogel is expanded through a fluid port. The hydrogel could saturate at a given fluid absorption level thereby allowing the addition or removal of fluid to expand or contract the coil without the hydrogel further expanding.
The devices disclosed herein can be designed to be disposed of after a single use, or they can be designed to be used multiple times. In either case, however, the device can be reconditioned for reuse after at least one use. Reconditioning can include any combination of the steps of disassembly of the device, followed by cleaning or replacement of particular pieces, and subsequent reassembly. In particular, the device can be disassembled, and any number of the particular pieces or parts of the device can be selectively replaced or removed in any combination. Upon cleaning and/or replacement of particular parts, the device can be reassembled for subsequent use either at a reconditioning facility, or by a surgical team immediately prior to a surgical procedure. Those skilled in the art will appreciate that reconditioning of a device can utilize a variety of techniques for disassembly, cleaning/replacement, and reassembly. Use of such techniques, and the resulting reconditioned device, are all within the scope of the present invention.
Preferably, the invention described herein will be processed before surgery. First, a new or used instrument is obtained and if necessary cleaned. The instrument can then be sterilized. In one sterilization technique, the instrument is placed in a closed and sealed container, such as a plastic or TYVEK bag. The container and instrument are then placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, ethylene oxide (EtO) gas, or high-energy electrons. The radiation kills bacteria on the instrument and in the container. The sterilized instrument can then be stored in the sterile container. The sealed container keeps the instrument sterile until it is opened in the medical facility.
It is preferred that the device is sterilized. This can be done by any number of ways known to those skilled in the art including beta or gamma radiation, ethylene oxide, steam, etc.
Any patent, publication, application or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated materials does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.
One of ordinary skill in the art will appreciate further features and advantages of the invention based on the above-described embodiments. Accordingly, the invention is not to be limited by what has been particularly shown and described, except as indicated by the appended claims. All publications and references cited herein are expressly incorporated herein by reference in their entirety.
This case is related to the following commonly assigned and concurrently filed U.S. Applications, all of which are hereby incorporated herein by reference: U.S. Ser. No. ______ (Attorney Docket Number END6514USNP) titled DEVICES and METHODS FOR ADJUSTING A SATIATION AND SATIETY-INDUCING IMPLANTED DEVICE; U.S. Ser. No. ______ (Attorney Docket Number END6515USNP) titled Sensor Trigger; U.S. Ser. No. ______ (Attorney Docket Number END6516USNP) titled AUTOMATICALLY ADJUSTING INTRA-GASTRIC SATIATION AND SATIETY CREATION DEVICE; U.S. Ser. No. ______ (Attorney Docket Number END6517USNP) titled OPTIMIZING THE OPERATION OF AN INTRA-GASTRIC SATIETY CREATION DEVICE; U.S. Ser. No. ______ (Attorney Docket Number END6518USNP) titled POWERING IMPLANTABLE DISTENSION SYSTEMS USING INTERNAL ENERGY HARVESTING MEANS; U.S. Ser. No. ______ (Attorney Docket Number END6519USNP) titled WEARABLE ELEMENTS FOR INTRA-GASTRIC SATIETY CREATION SYSTEMS; U.S. Ser. No. ______ (Attorney Docket Number END6520USNP) titled INTRA-GASTRIC SATIETY CREATION DEVICE WITH DATA HANDLING DEVICES AND METHODS; U.S. Ser. No. ______ (Attorney Docket Number END6521USNP) titled GUI FOR AN IMPLANTABLE DISTENSION DEVICE AND A DATA LOGGER; U.S. Ser. No. ______ (Attorney Docket Number END6522USNP) titled METHODS AND DEVICES FOR FIXING ANTENNA ORIENTATION IN AN INTRA-GASTRIC SATIETY CREATION SYSTEM; U.S. Ser. No. ______ (Attorney Docket Number END6523USNP) titled METHODS AND DEVICES FOR PREDICTING INTRA-GASTRIC SATIETY CREATION DEVICE SYSTEM PERFORMANCE; U.S. Ser. No. ______ (Attorney Docket Number END6524USNP) titled CONSTANT FORCE MECHANISMS for Regulating Distension Devices; U.S. Ser. No. ______ (Attorney Docket Number END6525USNP) titled A METHOD OF REMOTELY ADJUSTING A SATIATION AND SATIETY-INDUCING IMPLANTED DEVICE.